hormone therapy

The 31st Annual PCF Scientific Retreat highlighted significant advancements in understanding how diet and exercise can influence prostate cancer outcomes. Key findings suggest that a plant-based diet and regular physical activity can improve survivorship and reduce mortality rates. Ongoing clinical trials, such as INTERVAL-GAP4 and Prostate-8-II, aim to further explore these interventions' effects on patients with prostate cancer.

The OPTIMA trial investigates the use of the Prosigna test to predict which breast cancer patients may benefit from chemotherapy, aiming to personalize treatment plans. This phase 3 trial involves 4,500 participants and compares outcomes between standard chemotherapy and hormone therapy versus treatment guided by the Prosigna test. The study also evaluates the impact on patients' quality of life over time.

A phase 3 trial, PACE-B, reveals that five-fraction stereotactic body radiotherapy (SBRT) is non-inferior to conventional radiotherapy for low- to intermediate-risk localized prostate cancer.

Updated data from the RAMP 201 trial shows the combination of avutometinib and defactinib yields robust responses in recurrent low-grade serous ovarian cancer (LGSOC).

Researchers identified that mutations in the p53 gene are associated with resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer, and CDK2 inhibition may overcome this resistance.